Publication | Open Access
NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and HBeAg
33
Citations
0
References
2016
Year
Viral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyTreatment-naive Hbeag-positive PatientsNvr 3-778Antiviral ResponseAntiviral DrugHbv DnaMedicine
No additional data available for this publication yet. Check back later!